Home » Posts tagged with » Humira
Pfizer, AbbVie resolve IP matters for adalimumab biosimilar

Pfizer, AbbVie resolve IP matters for adalimumab biosimilar

Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters pertaining to the former’s proposed biosimilar of the latter’s rheumatoid arthritis drug Humira (adalimumab). Pfizer adalimumab biosimilar update As per the agreement terms, Pfizer has secured a non-exclusive patent license from AbbVie for the use […]

Mylan launches Humira biosimilar Hulio across Europe

Mylan has launched Hulio, a biosimilar to AbbVie’s Humira (adalimumab), in major markets in Europe, a month after its approval from the European Commission for all indications of the reference product. Hulio will be available to patients as early as possible, said Mylan, which partnered with Fujifilm Kyowa Kirin Biologics in April to commercialize the […]

Continue reading …
Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial

German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase 3 trial in patients with moderate-to-severe chronic plaque psoriasis. Cyltezo succeeded in the NCT 02850965 phase 3 trial by not showing any clinically meaningful differences in efficacy, safety and immunogenicity […]

Continue reading …
Hyrimoz EC approval : Novartis biosimilar of AbbVie Humira approved in EU

Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the reference drug including rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis and ulcerative colitis. The approval of Hyrimoz by European Commission (EC) was driven by analytical, preclinical and clinical research that […]

Continue reading …